Skip to main content
Haemonetics Corporation (HAE)
NYSE: HAE · Real-Time Price · USD
85.51
+0.59 (0.69%)
Nov 21, 2024, 1:48 PM EST - Market open

Haemonetics Revenue

Haemonetics had revenue of $345.51M in the quarter ending September 28, 2024, with 8.59% growth. This brings the company's revenue in the last twelve months to $1.36B, up 9.84% year-over-year. In the fiscal year ending March 30, 2024, Haemonetics had annual revenue of $1.31B with 12.01% growth.

Revenue (ttm)
$1.36B
Revenue Growth
+9.84%
P/S Ratio
3.17
Revenue / Employee
$372,224
Employees
3,657
Market Cap
4.29B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Mar 30, 20241.31B140.40M12.01%
Apr 1, 20231.17B175.46M17.67%
Apr 2, 2022993.20M122.73M14.10%
Apr 3, 2021870.46M-118.02M-11.94%
Mar 28, 2020988.48M20.90M2.16%
Mar 30, 2019 Pro Pro Pro
Mar 31, 2018 Pro Pro Pro
Apr 1, 2017 Pro Pro Pro
Apr 2, 2016 Pro Pro Pro
Mar 28, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
ICU Medical 2.34B
Integer Holdings 1.71B
Alkermes 1.51B
Ultragenyx Pharmaceutical 522.75M
ADMA Biologics 382.81M
Axsome Therapeutics 338.46M
TG Therapeutics 264.79M
BridgeBio Pharma 217.77M
Revenue Rankings

HAE News

More News